PT - JOURNAL ARTICLE AU - Nichols, Emma Hitt ED - Saver, Jeffrey L. TI - Addition of AMPLATZER PFO Occluder to Medical Therapy is Beneficial in Patients with Cryptogenic Stroke and PFO DP - 2013 May 01 TA - MD Conference Express PG - 18--19 VI - 13 IP - 1 4099 - http://mdc.sagepub.com/content/13/1/18.short 4100 - http://mdc.sagepub.com/content/13/1/18.full AB - Cryptogenic stroke remains a major challenge for clinicians taking care of patients who have had strokes. Patent foramen ovale (PFO) is a contributor to cryptogenic stroke due to paradoxical embolism [Furlan AJ et al. N Engl J Med 2012], but the optimal management strategy for PFO has yet to be defined [Kitsios GD et al. Stroke 2012]. This article reports the results of a follow-up analysis of the RESPECT PFO Clinical Trial [RESPECT; NCT00465270] to characterize the qualifying and endpoint ischemic strokes.